Medicines and Older People with Diabetes: Beliefs, Benefits and Risks

  • Trisha DunningEmail author


  • Most older people with diabetes use multiple medicines (polypharmacy).

  • Polypharmacy can be thoughtful and appropriate or ad hoc and inappropriate.

  • Medicine-related errors and adverse events are common causes of preventable hospital admissions for older people. Medicine-related adverse events also occur in hospital.

  • Hypoglycaemia is the most significant adverse event associated with glucose lowering medicines and can occur at any blood glucose level.

  • Medicine self-management becomes challenging with increasing age, functional, sensory and cognitive changes, access to health services and costs.

  • Blood glucose monitoring can be a useful management guide if it reflects the action profile of the prescribed glucose lowering medicines.


  1. Australian Commission on Safety and Quality in Healthcare (ACSQHC) (2011) National Safety and Quality Health Service Standards. ACSQHC, Canberra, pp 34–39Google Scholar
  2. Australian Institute of Health and Welfare (AIHW) (2009) Australian hospital statistics 2007–8. AIHW, CanberraGoogle Scholar
  3. Cheek D, Basshore L, Brazeau D (2015) Pharmacogenomic and implications for nursing practice. J Nurs Scholarsh 47(6):496–504CrossRefPubMedGoogle Scholar
  4. Commonwealth Department of Health and Aging (2002) The quality use of medicines. Commonwealth Department of Health and Aging, CanberraGoogle Scholar
  5. Cramer J, Roy A, Burrell A, Fairchild C, Fuldeore M, Ollendorf D, Wong P, International Society for Pharmacoeconomics for Outcomes Research Working Group (2007) Medication compliance and persistence: terminology and definitions. Value Health 11(1):4447Google Scholar
  6. Cryer P, Davis S, Shamoon H (2003) Hypoglycaemia in diabetes. Diabetes Care 26(6):1902–1912. CrossRefPubMedGoogle Scholar
  7. Davis T, Federman A, Bass P, Jackson R et al (2009) Improving patient understanding of prescription drug label instructions. J Gen Intern Med 24:57–62CrossRefPubMedGoogle Scholar
  8. Di Matteo M, Giordani P, Lepper H, Croghan T (2002) Patient adherence and medical treatment outcomes: a meta-analysis. Med Care 40(9):794–811CrossRefGoogle Scholar
  9. Diabetes Australia. (DA) (2011) A new language for diabetes: improving communication with and about people with diabetes. DA, CanberraGoogle Scholar
  10. Diabetes Control and Complications Trial Research Group (1993) The effect of intensive treatment of diabetes on the progression of long term complications of insulin dependent diabetes. N Engl J Med 329:977–986CrossRefGoogle Scholar
  11. Dickinson J, Guzman S, Melinda D et al (2017) The use of language in diabetes care and education. Diabetes Care. Scholar
  12. Dooley M, Wiseman M, McRae A et al (2011) Reducing potentially fatal errors associated with high doses of insulin: a successful multifaceted multidisciplinary prevention strategy. Br Med J.
  13. Dunning T (2003) Complementary therapies and diabetes. Complement Ther Nurs Midwifery 9:74–80CrossRefPubMedGoogle Scholar
  14. Dunning T, Manias E (2005) Medication knowledge and self-management by people with Type 2 diabetes. Aust J Adv Nurs 11:172–181Google Scholar
  15. Dunning T, Sinclair S (2014) Glucose lowering medicines and older people with diabetes: the importance of comprehensive assessments and pharmacovigilance. J Nurs Care 3(3):1–9Google Scholar
  16. Dunning T, Savage S, Duggan N. (2013) The McKellar guidelines for managing older people with residential and other care settings.
  17. Dunning T, Speight J, Bennett C (2017) Language, the ‘diabetes restricted code/dialect,’ and what it means for people with diabetes and clinicians. Diabetes Educ 47(1):18–26CrossRefGoogle Scholar
  18. Egede L, Xiaobou Y, Zheng D, Silverstein M (2002) The prevalence and pattern of complementary and alternative medicine use in individuals with diabetes. Diabetes Care 25:324–329CrossRefPubMedGoogle Scholar
  19. Eldred B, Dean A, McGuire T, Nash A (2006) Vaccine components and constituents: responding to consumer concerns. Med J Aust 2184(4):170–175Google Scholar
  20. Evrard A, Mbatchi L (2012) Genetic polymorphisms of drug metabolizing enzymes and transporters. The long way from bench to bedside. Curr Top Mol Chem 12(15):1720–1729CrossRefGoogle Scholar
  21. Fowler D. Rayman G. (2010) Safe and effective use of insulin in hospitalised patients. National Health Service London. Accessed Jan 2011
  22. Glisky E, Rubin S, Davidson S (2001) Source memory in older adults: an encoding or retrieving problem. J Exp Psychol 27(5):1131–1146Google Scholar
  23. Green J, Hawley J, Rask K (2007) Is the number of prescribing physicians an independent risk factor for adverse drug events in an elderly outpatient population? Am J Geriatr Pharmacother 5(1):31–39CrossRefPubMedGoogle Scholar
  24. Hilmer S, Gnijidic D, Le Couteur D (2013) Thinking through the medication list. Aust Fam Physician 12:924–928Google Scholar
  25. Institute of Safe Medicine Practice (ISMP) 2008. . Accessed Jan 2011.
  26. International Diabetes Federation (IDF) (2013) Language philosophy.
  27. Jenkins R, Vaida A. (2007) Simple strategies to avoid medication errors. AAFP . Accessed Dec 2009.
  28. Johnson J (2011) Drug target pharmacogenetics. Am J Pharmacogenomics 4:315–322Google Scholar
  29. Li F, Harmer P, Fisher J et al (2005) Tai chi and fall reduction in older adults: a randomized controlled trial. J Gerontol: Med Sci 60A(2):187–194CrossRefGoogle Scholar
  30. Lim L, McStea M, Chung W et al (2017) Prevalence, risk factors and health outcomes associated with polypharmacy among urban community-dwelling older adults in multi-ethnic Malaysia. PLoS One.
  31. Mallikarjun V, Swift J (2016) Therapeutic manipulation of ageing: repurposing old dogs and discovering new tricks. EBioMedicnine.
  32. Manya K, Champion B, Dunning T (2012) The use of complementary and alternative medicine among people living with diabetes in Sydney. BMC Complement Altern Med.
  33. Mosby’s Medical Dictionary (2009) 8th ed. Elservier.Google Scholar
  34. National Heart Foundation of Australia (NHFA) (2011) Improving Adherence in cardiovascular care. NHFAGoogle Scholar
  35. Newman B. (2010) Safety first. Nursing Rev 26Google Scholar
  36. O’Mahony D, O’Sullivan D, Byrne S et al (2015) STOPP/START criteria for potentially inappropriate prescribing in older people: version 2. Age Ageing 44(2):213–218. CrossRefPubMedGoogle Scholar
  37. Palliative Care—palliAGED (2017).
  38. Pearson E (2016) Personalized medicine in diabetes: the role of ‘omics’ and biomarkers. Diabet Med 13(6):712–717CrossRefGoogle Scholar
  39. Rogers E, Yost K, Rosedahl J et al (2017) Validating the patient experience with treatment self-management (PETS), a patient-reported measure of treatment burden, in people with diabetes. Patient Rel Outcome Meas 8:143–156CrossRefGoogle Scholar
  40. Rommers M, Teepe-Twiss I, Guchelaar H-J (2007) Preventing adverse drug events in hospital practice: an overview. Pharmacepidemiol Drug Saf 16:1129–1135CrossRefGoogle Scholar
  41. Roughead E, Lexchin J (2006) Adverse drug events: counting s not enough, action is needed. Med J Aust 184(7):315–316PubMedGoogle Scholar
  42. Sav A, Whitty J, McMillan S et al (2016) Treatment burden and chronic illness: who is most at risk? Patient 9(6):559–569CrossRefPubMedGoogle Scholar
  43. Savage S, Dunning T, Duggan N, Martin P (2012) The experiences and care preferences of people with diabetes at the end of life. J Hospice Palliative Care Nurs.
  44. Shrank W, Libeman J, Fischer M, Kiabuk E, Girdish C, Curtrona S, Brennan T, Chudhry N (2011) Are caregivers adherent to their own medications? J Am Pharm Assoc 51(4):492–498CrossRefGoogle Scholar
  45. Simpson S, Eurich D, Sadjeedp S, Ross I, Varney J, Johnson J (2006) A meta-analysis of the association between adherence to drug therapy and mortality. Br Med J 333:15–18CrossRefGoogle Scholar
  46. Sissung T, Goey A, Ley A et al (2014) Pharmacogenetics of membrane transporters: a review of current approaches. Methods Mol Biol 1175:91–120CrossRefPubMedGoogle Scholar
  47. Stowasser D, Allison Y, O’Leary Karen M (2004) Understanding the medicine management pathway. J Pharmacol Pract Res 34:293–296CrossRefGoogle Scholar
  48. The Pharmacy Guild of Australia (2010) Medindex: a medicine compliance indicator. The Pharmacy Guild of Australia, Canberra. Google Scholar
  49. United Kingdom National Prescribing Centre (2004) Task Force on Medicines Partnership. Drugs of porcine origin and their clinical alternatives. An introductory guide; March 2004. Available from:
  50. United Kingdom Prospective Study (UKPDS 33, 34) (1998) Intensive blood glucose control. Lancet 352(837–853):854–865Google Scholar
  51. Williams A, Manias E, Walker R (2008) Interventions to improve medication adherence in people with multiple chronic conditions: a systematic review. J Adv Nurs 63(2):132–143CrossRefPubMedGoogle Scholar
  52. Wolfstadt J, Gurwitz J, Field T, Lee M, Kalkar S, Wu W, Rochon P (2008) The effect of computerized physician order entry and clinical decision support on the rates of adverse drug events: a systematic review. J Gen Intern Med 23(4):451–458CrossRefPubMedPubMedCentralGoogle Scholar
  53. World health Organisation (WHO) (2003) Adherence to long-term therapies: evidence for action. WHO, GenevaGoogle Scholar
  54. Yasuda S, Zhang L, Huang S-M (2016) The role of ethnicity in variability in response to drugs: focus on clinical pharmacology. Stud Nat Pharmacol.
  55. Young-Hyman D, de Groot M, Hill-Briggs E et al (2016) Psychosocial care for people with diabetes: a position statement of the American Diabetes Association. Diabetes Care 29(12):2126–2140CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Centre for Quality and Patient Safety Research, Barwon Health PartnershipDeakin UniversityGeelongAustralia

Personalised recommendations